Canal-U

Mon compte

Résultats de recherche

Nombre de programmes trouvés : 586
Conférences

le (13m7s)

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Workshop 1 : New indications: Is heart failure a viable new potential indication for anti-thrombosis therapy (Efthymios DELIARGYRIS)

... pulmonary embolism as a cause of worsening HF is underestimated and certain underlying pathophysiological mechanisms are common to both arterial and venous thrombi. It has been recognized since long that HF is associated with hypercoagulable state, and, at...
Voir la vidéo
Conférences

le (52m37s)

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Workshop 1 : New indications: Is heart failure a viable new potential indication for anti-thrombosis therapy (Faiez ZANNAD)

... pulmonary embolism as a cause of worsening HF is underestimated and certain underlying pathophysiological mechanisms are common to both arterial and venous thrombi. It has been recognized since long that HF is associated with hypercoagulable state, and, at...
Voir la vidéo
Conférences

le (9m33s)

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Workshop 1 : New indications: Is heart failure a viable new potential indication for anti-thrombosis therapy (Krishna PRASAD)

... pulmonary embolism as a cause of worsening HF is underestimated and certain underlying pathophysiological mechanisms are common to both arterial and venous thrombi. It has been recognized since long that HF is associated with hypercoagulable state, and, at...
Voir la vidéo
Label UNT Conférences

le (57m35s)

Cardiovascular Clinical Trialists (CVCT) Forum - Paris 2012 : SHIfTing evidence in heart failure management.

Title : Cardiovascular Clinical Trialists (CVCT) Forum - Paris 2012 : SHIfTing evidence in heart failure management.Speaker: Jeffrey BORER, New York, USAAbstract : SHIFT (Systolic Heart failure treatment with the If inhibitor ivabradine Trial) involved 6505 patients with moderate to severe heart failure (HF), heart rate ?70bpm in sinus rhythm, at least one HF hospitalization during the year prior to study, and LVEF ?35% who were receiving guidelinesbased HF therapy including maximized beta blockade, who were randomized to add either placebo or ivabradine (pure HR slowing drug) during a median 22.9 months follow-up. The results of SHIFT unambiguously demonstrated the benefits of HR ...
Voir la vidéo
Label UNT Conférences

le (3m24s)

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : Debate led by Journal Editors: There are too many studies and the quality is variable. Should there be a position statement establishing rules for biomarker studies?

...Title : Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : Debate led by Journal Editors: There are too many studies and the quality is variable.Should there be a position statement establishing rules for biomarker studies?John JARCHO,...
Voir la vidéo
Label UNT Conférences

le (4m2s)

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : Debate led by Journal Editors: There are too many studies and the quality is variable. Should there be a position statement establishing rules for biomarker studies?

...Title : Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : Debate led by Journal Editors: There are too many studies and the quality is variable.Should there be a position statement establishing rules for biomarker studies?John JARCHO,...
Voir la vidéo

 
FMSH
 
Facebook Twitter Google+
Mon Compte